Zanubrutinib Safe, Effective in Real-World CLL/SLL Cohort

New real-world data support the safety and efficacy of zanubrutinib (Brukinsa; BeOne) in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL), regardless of whether they have previously been treated with ibrutinib…